logo

For the Inventor, By the Inventor

Middletown, MD, United States of America

Hsiang-fu Kung

This inventor holds 4 USPTO granted patents. Top assignees: American Biosciences, Inc., New York University, The United States of America as Represented by the Department of Health. Active years: 1994-1997.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hsiang-fu Kung. Retrieved from https://idiyas.com/inventor/hsiang-fu-kung-71h0e454

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 4

% Patents Active = 100.0

Average Co-Inventor Count = 6.1

ph-index = 3

Forward Citations = 23(Granted Patents)


Company Filing History:

goldMedal3 out of 3 
 
American Biosciences, Inc.
 patents
silverMedal3 out of 1,731 
 
New York University
 patents
bronzeMedal2 out of 1,217 
 
The United States of America as Represented by the Department of Health
 patents
4. 1 out of 2,202 
 
The United States of America as Represented by the Secretary of
 patents
5. 1 out of 3,699 
 
The United States of America, as Represented by the Secretary, Department of Health and Human Services
 patents
where one patent can have more than one assignee

Years Active: 1994-1997

Loading Chart...
4 patents (USPTO):Explore Patents
1. 5668149 - Inhibition of human immunodeficiency virus-1 infectivity in human cells (1997-09-16),
2. 5532214 - Anti-HIV protein, TAP 29, from tricosanthes, DNA coding therefor and (1996-07-02),
3. 5484889 - Plant protein useful for treating tumors and HIV infection (1996-01-16),
4. 5317009 - Anti-HIV proteins GAP 31, DAP 30 and DAP 32 and therapeutic uses thereof (1994-05-31),

Title: Hsiang-fu Kung: Innovator in HIV Research

Introduction

Hsiang-fu Kung is a notable inventor based in Middletown, MD (US). He has made significant contributions to the field of HIV research, holding a total of 4 patents. His work focuses on innovative methods to combat HIV-1 infectivity in human cells.

Latest Patents

Kung's latest patents include groundbreaking methods for inhibiting the infectivity of HIV-1 in human cells. These methods involve the use of certain quinolinyl and acridinyl derivatives, such as amodiaquin, chloroquine, hydroxychloroquine, primoquine, and quinacrine. Additionally, he has developed a new protein, termed TAP 29, which is derived from the root tuber of the plant Trichosanthes kirilowii. This protein is useful for treating HIV infections or tumors and can be administered alone or alongside conventional AIDS therapies.

Career Highlights

Throughout his career, Hsiang-fu Kung has worked with prestigious institutions, including New York University and American Biosciences, Inc. His research has significantly advanced the understanding and treatment of HIV.

Collaborations

Kung has collaborated with notable colleagues, including Sylvia Lee-Huang and Paul L Huang. Their combined efforts have contributed to the development of innovative solutions in the fight against HIV.

Conclusion

Hsiang-fu Kung's contributions to HIV research through his patents and collaborations highlight his role as a key innovator in the field. His work continues to pave the way for advancements in treatment options for HIV infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…